Compare Keysight Technologies Inc (KEYS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Viatris Inc — how do they compare? Keysight Technologies Inc trades at $346.15 (market cap $58.74B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Keysight Technologies Inc is far larger — about 3.1× Viatris Inc's market cap, and Viatris Inc pays a 2.95% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals.
| KEYS | VTRS | |
|---|---|---|
Market Cap | $58.74B | $18.69B |
Sector | Technology | Health |
52-Week High | $373.34 | $17.86 |
52-Week Low | $158.51 | $9.49 |
Enterprise Value | $59.08B | $30.80B |
Dividend Yield | — | 2.95% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
